Kangzhe Pharmaceuticals: In July 2026, obtained the clinical trial approval for innovative drug CMS-D017 AMD indication.

Kangzhe Pharmaceutical announced that the company's independently developed innovative drug complement factor B inhibitor CMS-D017 capsules obtained the drug clinical trial approval notice issued by the China National Medical Products Administration on July 15, 2026, allowing the clinical trial for the treatment of age-related macular degeneration. Previously, CMS-D017 had obtained clinical trial approval notices for paroxysmal nocturnal hemoglobinuria and complement-mediated kidney diseases on January 30 and February 3, 2026, respectively.